Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

17 Sept 2015

Abstract excerpt

UNLABELLED: Pharmacologically-induced activation of replication competent proviruses from latency in the presence of antiretroviral treatment (ART) has been proposed as a step towards curing HIV-1 infection. However, until now, approaches to reverse HIV-1 latency in humans have yielded mixed results. Here, we report a proof-of-concept phase Ib/IIa trial where 6 aviremic HIV-1 infected adults received intravenous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV-related health complications and treatments
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26379282
DOI: 10.1371/journal.ppat.1005142

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Depsipeptide Romidepsin Reverses HIV-1 Latency In VivoPMID 26379282Read ↗

Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individualsSemantic proximity Read ↗

Histone Deacetylase Inhibitor Romidepsin Inhibits<i>De Novo</i>HIV-1 InfectionsSemantic proximity Read ↗

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations.Semantic proximity Read ↗

Inhibition of ALKBH5 demethylase of m6A pathway potentiates HIV-1 reactivation from latencySemantic proximity Read ↗

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trialSemantic proximity Read ↗

High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR AssaySemantic proximity Read ↗

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinationsSemantic proximity Read ↗

Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing AgentsSemantic proximity Read ↗

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latencySemantic proximity Read ↗

Characterization of Inducible Transcription and Translation-Competent HIV-1 Using the RNAscope ISH Technology at a Single-Cell ResolutionSemantic proximity Read ↗

Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulationsSemantic proximity Read ↗

RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.